JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 93 filers reported holding JOUNCE THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $166,870 | -37.5% | 90,200 | +182.3% | 0.01% | -33.3% |
| Q4 2021 | $267,000 | +12.7% | 31,952 | 0.0% | 0.01% | +12.5% |
| Q3 2021 | $237,000 | +9.2% | 31,952 | 0.0% | 0.01% | +14.3% |
| Q2 2021 | $217,000 | +27.6% | 31,952 | +93.0% | 0.01% | +16.7% |
| Q1 2021 | $170,000 | +56.0% | 16,552 | +6.4% | 0.01% | +20.0% |
| Q4 2020 | $109,000 | -9.2% | 15,552 | +6.1% | 0.01% | -16.7% |
| Q3 2020 | $120,000 | +18.8% | 14,652 | 0.0% | 0.01% | 0.0% |
| Q2 2020 | $101,000 | +44.3% | 14,652 | 0.0% | 0.01% | +20.0% |
| Q1 2020 | $70,000 | -45.3% | 14,652 | 0.0% | 0.01% | -28.6% |
| Q4 2019 | $128,000 | +68.4% | 14,652 | -35.7% | 0.01% | +40.0% |
| Q3 2019 | $76,000 | -32.7% | 22,800 | 0.0% | 0.01% | -28.6% |
| Q2 2019 | $113,000 | +22.8% | 22,800 | +54.1% | 0.01% | +16.7% |
| Q1 2019 | $92,000 | – | 14,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BML Capital Management, LLC | 1,087,961 | $2,012,728 | 1.74% |
| Opaleye Management Inc. | 2,880,000 | $5,328,000 | 1.60% |
| TANG CAPITAL MANAGEMENT LLC | 5,300,087 | $9,805,161 | 1.46% |
| Ardent Capital Management, Inc. | 923,463 | $1,708,407 | 1.23% |
| Beryl Capital Management LLC | 610,831 | $1,130,037 | 0.89% |
| Arena Investors LP | 610,639 | $1,129,682 | 0.88% |
| Omega Fund Management, LLC | 275,513 | $509,699 | 0.33% |
| Deep Track Capital, LP | 4,259,653 | $7,880,358 | 0.32% |
| PenderFund Capital Management Ltd. | 246,310 | $616 | 0.19% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 425,100 | $786,435 | 0.15% |